nDatalyze マネジメント

マネジメント基準チェック /34

nDatalyzeの CEO はJames Durwardで、 Jan2018年に任命され、の在任期間は 6.83年です。は、会社の株式の19.98%を直接所有しており、その価値はCA$ 762.89K 。経営陣と取締役会の平均在任期間はそれぞれ5.6年と6.7年です。

主要情報

James Durward

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	6.8yrs
CEOの所有権	20.0%
経営陣の平均在職期間	5.6yrs
取締役会の平均在任期間	6.7yrs

経営陣の近況

Recent updates

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Jan 14

CEO報酬分析

nDatalyze の収益と比較して、James Durward の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Aug 31 2024	n/a	n/a	-CA$668k
May 31 2024	n/a	n/a	-CA$310k
Feb 29 2024	n/a	n/a	-CA$156k
Nov 30 2023	n/a	n/a	-CA$550k
Aug 31 2023	n/a	n/a	-CA$612k
May 31 2023	n/a	n/a	-CA$1m
Feb 28 2023	CA$27k	CA$27k	-CA$1m
Nov 30 2022	n/a	n/a	-CA$2m
Aug 31 2022	n/a	n/a	-CA$2m
May 31 2022	n/a	n/a	-CA$1m
Feb 28 2022	n/a	n/a	-CA$1m
Nov 30 2021	n/a	n/a	-CA$918k
Aug 31 2021	n/a	n/a	-CA$895k
May 31 2021	n/a	n/a	-CA$785k
Feb 28 2021	CA$184k	CA$5k	-CA$699k
Nov 30 2020	n/a	n/a	CA$7k
Aug 31 2020	n/a	n/a	CA$39k
May 31 2020	n/a	n/a	-CA$2k
Feb 29 2020	CA$43k	CA$25k	-CA$37k
Nov 30 2019	n/a	n/a	-CA$47k
Aug 31 2019	n/a	n/a	-CA$100k
May 31 2019	n/a	n/a	-CA$82k
Feb 28 2019	CA$87k	CA$25k	-CA$237k

報酬と市場: Jamesの総報酬がCanadian市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Jamesの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

James Durward (69 yo)

6.8yrs

在職期間

CA$26,500

報酬

Mr. James Morris Durward serves as Chief Executive Officer, Corporate Secretary and Director at nDatalyze Corp. (formerly known as MedXtractor Corp.) since January 24, 2018 and served as its President unti...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
James Durward	Chief Technical Officer	6.8yrs	CA$26.50k	19.98% CA$ 762.9k
Dwayne Vinck	Chief Financial Officer	5.6yrs	CA$21.69k	1.96% CA$ 74.9k
Keith Courtney	Chief Psychiatric Officer	less than a year	データなし	データなし

5.6yrs

平均在職期間

経験豊富な経営陣: NDATの経営陣は経験豊富で経験豊富です（平均在職期間は5.6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
James Durward	Chief Technical Officer	6.8yrs	CA$26.50k	19.98% CA$ 762.9k
G. Price	Independent Director	6.8yrs	データなし	2.71% CA$ 103.5k
Dusan Kuzma	Independent Director	6.7yrs	データなし	0.50% CA$ 19.0k
Gordon Crawford	Independent Director	4yrs	データなし	2.59% CA$ 99.0k

6.7yrs

平均在職期間

69yo

平均年齢

経験豊富なボード: NDATの取締役会は経験豊富であると考えられます ( 6.7年の平均在任期間)。

nDatalyze マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

nDatalyze Corp. Announces Change in President

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Insufficient new directors

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

Recent updates

Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.004 profit in 2Q 2024)

nDatalyze Corp. Announces Positive Clinical Study Results, and Mindbalanced Update

New minor risk - Share price stability

nDatalyze Corp. Announces Change in President

Full year 2024 earnings released: CA$0.004 loss per share (vs CA$0.032 loss in FY 2023)

nDatalyze Corp. Announces Clinical Study Update

nDatalyze Corp. Updates the Clinical Study

nDatalyze Corp. announced that it has received CAD 0.20625 million in funding

nDatalyze Corp. announced that it expects to receive CAD 0.20625 million in funding

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp. (CNSX:NDAT) completed the acquisition of Mindbalanced Inc.

New minor risk - Share price stability

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

nDatalyze Corp. announced that it has received CAD 0.2778 million in funding

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2023)

nDatalyze Corp. Advances Its Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

Full year 2023 earnings released: CA$0.032 loss per share (vs CA$0.032 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.001 loss in 3Q 2022)

nDatalyze Corp. Anticipates YMI ChatGPT Testing

nDatalyze Corp. Announces Two Video Initiatives to Augment Its Phase 2 Marketing Program

nDatalyze Corp. Announces Canada-Wide Release of YMI

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 2Q 2022)

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.002 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.032 loss per share (vs CA$0.027 loss in FY 2021)

nDatalyze Announces YMI mHealth Application Beta is Now Online

nDatalyze Corp. announced that it expects to receive CAD 1.25 million in funding

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

nDatalyze Announces Successful Proof-Of-Concept and Progress Update

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 profit in 2Q 2021)

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.001 profit in 1Q 2021)

Medxtractor Corp Updates Reference Record Collection Progress

Full year 2021 earnings released: CA$0.027 loss per share (vs CA$0.002 loss in FY 2020)

MedXtractor Corp. announced that it has received CAD 1.815 million in funding

President exercised options and sold CA$78k worth of stock

Chief Financial Officer recently sold CA$99k worth of stock

New 90-day high: CA$0.27

MedXtractor Corp. announced that it expects to receive CAD 1.6 million in funding

Medxtractor Corp. Updates the SHAMAN Psychedelics Artificial Intelligence Project

New 90-day high: CA$0.24

New 90-day high: CA$0.21

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Medxtractor Corp. Announces Commencement of "SHAMAN"

Third quarter 2021 earnings released: CA$0.001 loss per share

MedXtractor Corp. Announces Board Changes

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34